Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

Status: Recruiting
Location: See all (56) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

TECNO is a multicenter, prospective, randomized, open label, blinded endpoint (PROBE) proof-of-concept trial evaluating if additional administration of intra-arterial Tenecteplase (TNK) improves reperfusion in patients with incomplete mechanical thrombectomy (MT). For this purpose, 156 adult participants experiencing an acute ischemic stroke due to a large vessel occlusion with incomplete reperfusion with residual occlusions after MT will be randomly assigned to receive 3mg intra-arterial (IA) TNK or best medical treatment. Recruitment will occur at 20 academic tertiary stroke care centers in Switzerland, Spain, Belgium, and Germany and patients are followed up for 90 days after the index event. Showing superiority for reperfusion outcomes would have a major impact on the future management of stroke patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Informed consent

• Age ≥18 years

• Clinical signs consistent with an acute ischemic stroke

• Patient had an initial vessel occlusion in the anterior or posterior circulation defined as intracranial ICA, M1, M2, M3, A1, A2, P1 or P2

• Patient has undergone endovascular stroke treatment

• Onset to randomization no later than \< 705 minutes (11h 45min) after symptom-onset/last-seen well.

• Incomplete reperfusion defined as any of the following:

‣ For ICA/M1: TICI2b/2c (50-99%) reperfusion after endovascular treatment without mechanically amendable target-occlusion (as per definition by the interventionalist).

⁃ For A1/A2, P1/P2, M2/M3: TICI2a/2b/2c (1-99%) reperfusion after endovascular treatment without mechanically amendable target-occlusion (as per definition by the interventionalist).

⁃ Any emboli to new territory without mechanically amendable target-occlusion (as per definition by the interventionalist).

• Signs of early ischemic changes of non-contrast CT Alberta Stroke Program Early CT Score (ASPECTS) ≥5 (for DWI-ASPECTS ≥ 4, for DWI-ASECTS: a region must have diffusion abnormality in 20% or more of its volume to be considered DWI-ASPECTS positive)

Locations
Other Locations
Austria
LKH-Universitätsklinikum Graz
RECRUITING
Graz
Medizinische Universität Innsbruck
RECRUITING
Innsbruck
Kepler Universitätsklinikum GmbH
RECRUITING
Linz
Christian-Doppler-Klinik Salzburg
RECRUITING
Salzburg
Belgium
Hôpital universitaires de Bruxelles
RECRUITING
Anderlecht
AZ Sint Jan Brugge AV
RECRUITING
Bruges
Cliniques universitaires Saint-Luc
RECRUITING
Brussels
UZ Brussel
RECRUITING
Brussels
Universitair Ziekenhuis Gent
RECRUITING
Ghent
UZ Gasthuisberg Leuven
RECRUITING
Leuven
Clinique CHC MontLégia
RECRUITING
Liège
Finland
University Hospital Helsinki
RECRUITING
Helsinki
Germany
Universitätsklinikum Augsburg
RECRUITING
Augsburg
Universitätsklinikum Bonn
RECRUITING
Bonn
Klinikum Bremen-Mitte
RECRUITING
Bremen
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
RECRUITING
Dresden
Helios Klinikum Erfurt
RECRUITING
Erfurt
Universitätsklinikum Frankfurt
RECRUITING
Frankfurt
Universitätsklinikum Freiburg
RECRUITING
Freiburg Im Breisgau
Universitätsmedizin Göttingen
RECRUITING
Göttingen
Universitätsklinikum Halle (Saale)
RECRUITING
Halle
Asklepios Klinik Altona
RECRUITING
Hamburg
Universitätsklinikum Hamburg-Eppendorf
RECRUITING
Hamburg
Universitätsklinikum Schleswig-Holstein Campus Kiel
RECRUITING
Kiel
Universitätsklinikum Magdeburg A. ö. R.
RECRUITING
Magdeburg
Universitätsmedizin Mannheim
RECRUITING
Mannheim
Johannes Wesling Klinikum Minden
RECRUITING
Minden
Klinikum der Universität München
NOT_YET_RECRUITING
München
Klinikum rechts der Isar der Technischen Universität München
NOT_YET_RECRUITING
München
Universitätsklinikum Münster
NOT_YET_RECRUITING
Münster
Städtisches Klinikum Sollingen
RECRUITING
Solingen
Universitätsklinikum Tübingen
RECRUITING
Tübingen
Netherlands
Amsterdam UMC
NOT_YET_RECRUITING
Amsterdam
Leiden UMC
NOT_YET_RECRUITING
Leiden
Maastricht UMC
NOT_YET_RECRUITING
Maastricht
Haaglanden MC
NOT_YET_RECRUITING
The Hague
Portugal
Hospital de Braga
NOT_YET_RECRUITING
Braga
University Hospital of Coimbra
NOT_YET_RECRUITING
Coimbra
Hospital Nelio Mendonca Funchal
RECRUITING
Funchal
Hospital Eagas Moniz
NOT_YET_RECRUITING
Lisbon
Hospital Lisbon North (Santa Maria)
NOT_YET_RECRUITING
Lisbon
Lisbon Central University Hospital
RECRUITING
Lisbon
Hospital de São João
NOT_YET_RECRUITING
Porto
Hospital Santo Antonio
NOT_YET_RECRUITING
Porto
Hospital de Vila Nova de Gaia
NOT_YET_RECRUITING
Vila Nova De Gaia
Switzerland
Kantonsspital Aarau
RECRUITING
Aarau
Kantonsspital Aarau AG
RECRUITING
Aarau
Universitätsspital Basel
RECRUITING
Basel
Universitätsspital Bern
RECRUITING
Bern
Hôpitaux universitaires de Genève
RECRUITING
Geneva
Centre Hospitalier Universitaire Vaudois
RECRUITING
Lausanne
Centre Hospitalier Universitaire Vaudois (CHUV)
RECRUITING
Lausanne
Kantonsspital Luzern
RECRUITING
Lucerne
Ospedale Regionale di Lugano
RECRUITING
Lugano
Kantonsspital St.Gallen
RECRUITING
Sankt Gallen
Universitätsspital Zürich
RECRUITING
Zurich
Contact Information
Primary
Urs Fischer, Prof
urs.fischer@insel.ch
+41316327305
Backup
Seraina Martina Beyeler, PhD
nctu@insel.ch
+41316323970
Time Frame
Start Date: 2023-03-21
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 156
Treatments
No_intervention: Best Medical Treatment (standard of care)
Patients will receive standard of care as per current ESO guidelines.
Experimental: Intra-arterial Tenecteplase
Patients will receive intra-arterial administration of Tenecteplase using a standard approved microcatheter.
Related Therapeutic Areas
Sponsors
Leads: Insel Gruppe AG, University Hospital Bern

This content was sourced from clinicaltrials.gov